Juq-279: ~repack~

JUQ‑279 is a potent, selective PI3K‑β inhibitor with robust pre‑clinical efficacy against TNBC models and a favorable safety profile, supporting progression to IND‑enabling studies.

Maki Hojo (Houjou Maki), a prominent performer known for "mature woman" ( jukujo ) roles. JUQ-279

Triple‑negative breast cancer (TNBC) lacks estrogen‑, progesterone‑, and HER2‑receptor expression, limiting targeted therapeutic options. The phosphoinositide 3‑kinase (PI3K)/AKT/mTOR pathway is frequently hyper‑activated in TNBC, representing a compelling target. JUQ‑279 is a potent, selective PI3K‑β inhibitor with

One of the challenges in studying JUQ-279 and similar research chemicals is the limited availability of information on their effects, both beneficial and adverse. This underscores the need for comprehensive research that prioritizes safety and efficacy. Future directions for research on JUQ-279 could include detailed pharmacological studies, exploration of its therapeutic potential in preclinical models, and elucidation of its mechanism of action. Collaborative efforts between chemists, pharmacologists, and clinicians will be essential in unlocking the full potential of JUQ-279. Future directions for research on JUQ-279 could include